Patients on vitamin K treatment: is switching to direct-acting oral anticoagulation cost-effective? A target trial on a prospective cohort

Patients on vitamin K treatment: is switching to direct-acting oral anticoagulation cost-effective? A target trial on a prospective cohort

Aims Direct-acting oral anticoagulants (DOACs) have, to a substantial degree, replaced vitamin K antagonists (VKA) as treatments for stroke prevention in atrial fibrillation (AF) patients. However, evidence on the real-world causal effects of switching patients from VKA to DOAC is lacking. We aimed...

Full description

Bibliographic Details
Main Authors: Stefanie Aeschbacher, David Conen, Stefan Osswald, Andreas Mueller, Tobias Reichlin, Christian Sticherling, Michael Kuhne, Matthias Schwenkglenks, Eva Blozik, Nicolas Rodondi, Giorgio Moschovitis, Carola A Huber, Michael Coslovsky, Marcello Di Valentino, Thomas D Szucs, Maria Luisa De Perna, Giulio Conte, Juerg H Beer, Miquel Serra-Burriel, Leo Bonati, Manuel Blum, Helena Aebersold, Stefan Felder, Rebecca E Paladini, Annina Stauber, Fabienne Foster-Witassek
Format: Article
Language:English
Published: BMJ Publishing Group 2024-01-01
Series:Open Heart
Online Access:https://openheart.bmj.com/content/11/1/e002567.full

Internet

https://openheart.bmj.com/content/11/1/e002567.full

Similar Items